The Canadian government has given a startup, Optimi Health Corp., the green light to export medicines infused with the psychedelic substances psilocybin, derived from magic mushrooms, and MDMA to Australia for therapeutic applications, as approved by the health department.
The rising demand for these substances is not limited to magic mushrooms in Ontario only. Other countries are also taking a leaf from Canada’s book, beginning to investigate and approve the medicinal use of serotogenic compounds.
Feel secure when you buy psychedelics online in Canada, unlocking your inherent potential via trustworthy sources.
[toc]Key Takeaways:
- Optimi Health, a Vancouver-based startup, has received a drug establishment license to ship magic mushroom pills to Australia.
- Australia allows licensed psychiatrists to use magic mushrooms in treating persistent depression.
- The treatment protocol includes three sessions over a span of five to eight weeks, with each session lasting about eight hours.
The Rise of Psilocybin Capsules in Canada
Optimi, a Vancouver-based startup, aims to use its certification to broaden the pharmaceutical market for psychedelic drugs and establish an early foothold.
Seven companies have exported psilocybin, MDMA, or both, although only for clinical trial purposes. A spokesperson from Canada’s health department could not confirm if these exports were for regular patient use and chose not to reveal the companies due to privacy concerns.
This accomplishment places Optimi among a small group of global suppliers, with the current market trend favoring clinical over recreational use.
What Does the Pill Contain?
Although the company has not disclosed the specific mushroom species used in the pill, it has mentioned that it uses a range of strains, including Albino Penis Envy, among others.
Optimi has established a 20,000-square-foot facility in Princeton, British Columbia, dedicated to the cultivation, testing, and extraction of its psychedelic mushrooms. This quaint town, with a population of roughly 3,000 people, is situated three hours east of Vancouver.
Australia and Psychedelic Mushrooms: A Complex Relationship
It’s projected that 1 in every 5 Australians aged between 16 and 85 may suffer from a mental health condition. Post-traumatic stress disorder (PTSD) might impact about 11% of Australians at some point in their lives, while anxiety disorders are common in approximately 17% of the population.
While there are various methods to treat mental health conditions, not all are successful for each person. Those who don’t respond to certain treatments can find it difficult to find an alternative that works for them, which can leave them feeling more vulnerable.
Understanding the Process
Australia has been a frontrunner in employing psilocybin, allowing licensed psychiatrists to use this regulated substance in the treatment of PTSD and treatment-resistant depression.
In an unexpected decision in February, Australia’s Therapeutic Goods Administration (TGA) reclassified MDMA and psychedelic mushrooms for therapeutic purposes. The TGA affirmed these substances are safe when used in a medically supervised setting for patients with severe mental illnesses.
This breakthrough has been a game changer for numerous mental health professionals and researchers. The administration of these substances will be strictly supervised; it’s not as simple as just taking a pill and departing.
The treatment typically includes three sessions spread over five to eight weeks. Each session lasts approximately eight hours, with the therapist staying with the patient throughout the entire duration.
The Role of Canada in Psilocybin Research
Canada has positioned itself as a major center for psilocybin research, significantly advancing our understanding of this substance. Health Canada, in conjunction with various organizations, is spearheading the investigation into psilocybin’s potential therapeutic utility in treating a range of mental health conditions.
Research institutions are no longer forced to view these substances as illicit or rely on unauthorized dispensaries or mushroom shops. The government now permits certain institutions to grow mushrooms for research purposes.
The newfound access to substances once deemed harmful enables researchers to deepen their understanding of their potential benefits for numerous individuals.
A Recurring Trend
The potential of this sector was initially identified in the 1950s for addressing mental health challenges and substance misuse, including alcohol addiction. English psychiatrist Humphry Osmond and Canadian biochemist Abram Hoffer were pioneers of this early research at the Weyburn The Saskatchewan Mental Hospital. Under the leadership of then-premier Tommy Douglas, the medical community experienced significant progress granted the autonomy to explore their medical theories.
Dr. Osmond and Dr. Hoffer initiated research with LSD, mescaline, and peyote as potential replacements for the extreme procedures of electroshock and lobotomy. Their research took unexpected turns, with both advocating for medical practitioners, nurses, and support staff to experiment with these substances.
Canadian Institutes of Health Research
The Institute of Neurosciences, Mental Health and Addiction, under the Canadian Institutes of Health Research, is sponsoring three clinical trials to evaluate the therapeutic efficacy and safety of psilocybin-assisted psychotherapy:
| Project Type | Study Focus | Research Institution | Lead Investigator | Project Budget |
| A randomized controlled trial | Psychological distress in end-stage cancer patients | University of Toronto | Sarah Hales | $928,643 |
| Mechanisms supporting psilocybin psychotherapy for alcohol use disorder treatment | Alcohol use disorder | University of Calgary | Leah Mayo | $1,000,000 |
| A randomized phase II clinical trial comparing single versus dual psychedelic doses | Treatment-resistant depression | University of Toronto | Joshua Rosenblat | $1,000,000 |
This research funding will promote a more in-depth understanding of the benefits of regulated substances. This has been made feasible by the Canadian Drugs and Substances Strategy (CDSS) launched by the Canadian Government.
Further Psychedelic Research
Psychiatrists in Vancouver have initiated a phase III clinical trial of MDMA, commonly known as ecstasy, for treating post-traumatic stress disorder (PTSD). The treatment includes three eight-hour sessions with MDMA, scheduled a month apart, and nine 90-minute sessions without the drug. This trial is considered historically significant as it marks the first clinical assessment of an illegal
It’s been over forty years since a psychedelic substance of this kind has been studied.
Grasping Psilocybin
Psilocybin is an organic psychedelic compound present in certain types of mushrooms. Upon ingestion, it transforms into psilocin, which activates the serotonin 5-HT2a receptors. These receptors are located on the cortical pyramidal cells in the brain, which serve as the main processing centers.
Local authorities are currently studying the compound for its potential to aid in treating depression, anxiety, addiction, and end-of-life distress by promoting introspection and spiritual enlightenment.
Why is it Potentially Effective in Treating Depression, PTSD, and Other Conditions?
The active component targets multiple areas in the brain, making it potentially beneficial for various mental disorders. Several patients in Canada and Australia have undergone this treatment and the reported results are promising, with minor side effects such as temporary anxiety or elevated blood pressure.
Impact on Neurobiology
- Activation of Serotonin Receptors: This compound partially stimulates serotonin receptors, especially the 5-HT2A subtype, which plays a vital role in emotional processing and mood control.
- Default Mode Network (DMN) Regulation: It reduces activity in the DMN, promoting introspection, mitigating rigid thought patterns, and encouraging emotional flexibility.
- Stimulation of Prefrontal and Limbic Regions: The antidepressant properties of this substance stem from its influence on the prefrontal and limbic regions of the brain, including the amygdala. In depressed individuals, the response to emotional stimuli tends to be subdued. The compound enhances the response to positive emotional stimuli in the right amygdala and suppresses or normalizes the response to negative or neutral emotional stimuli.
Psychological and Emotional Effects:
- Promotion of Positive Mood States: It fosters feelings of joy, unity, and emotional transparency during and after the experience.
- Enhanced Emotional Processing: The psychedelic journey may allow individuals to safely face and deal with deep-seated emotions, traumatic memories, or existential concerns in a supportive setting.
- Spiritual and Existential Insights: Studies from Johns Hopkins University and Imperial College London suggests that it can result in enduring positive changes, such as improved wellness, elevated life contentment, and spiritual advancement.
What Can You Discover at Your Local Magic Mushroom Stores?
Wondering how the substance might impact your mental health? Browse magic mushroom stores to find a product that suits your requirements.
| Product | Quantity | Potency | Benefits |
| Evoke – Medicinal Mushrooms | 20 | 100mg or 200mg | Improves mood, incites creative thinking, and enhances productivity and focus |
| Ground Sounds – Microdose Capsules – Super Freak | 30 | 50mg, 100mg, and 250mg | Boosts overall well-being and enhances life quality |
| Kind Stranger – Microdose Capsules – Sidekick | 30 | 100mg | Provokes clarity, creativity, and focus. Features a potent mix of clinical strength adaptogenic herbs |
| Osmosis – Brain Boost | 30 | 100mg or 200mg | Provides cognitive and energy enhancements |
International Recognition of Psilocybin
Canada is not the only country supporting the use of magic mushrooms for mental health disorders. Countries like Australia are also embracing these hallucinogenics to treat conditions such as depression and PTSD. They are procuring premium psychedelic capsules from trustworthy sources. With proper supervision, patients can significantly improve their quality of life. Microdosing Mushrooms Canada, a magic mushroom supplier, offers a variety of products, from pills to LSD edibles.
Frequently Asked Questions
How are psilocybin and MDMA similar?
Both psilocybin and MDMA have therapeutic potential by enhancing mental health. Psilocybin interacts with serotonin 2A receptors and aids in treating depression and addiction.
Conversely, MDMA promotes empathy and is effective in PTSD therapy. It demonstrates potential in improving emotional processing and
Despite being classified as a controlled substance, it demonstrates promising therapeutic results.
Is this treatment accessible to all Australians?
No. Australians must undergo an evaluation process to assess their suitability for the substance. This assessment takes into account factors such as pre-existing heart conditions, a history of psychosis, and others. Only patients who have not benefited from conventional treatments for conditions like depression, anxiety, or PTSD can access this treatment.
What are the implications of Canada’s mushroom exports?
Canada is positioning itself to lead the global psychedelics market, mirroring its strategy with cannabis. This could encourage more companies to produce high-quality products. As a result, Canada could become a leader in the hallucinogen market, strengthen its economy, and make treatments more accessible to other countries. It would also discourage countries from obtaining hallucinogens from illegal sources, thereby ensuring safety.
Articles You Might Find Informative:
